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Kinetics of peritoneal protein loss during CAPD: II.
Lipoprotein leakage and its impact on plasma lipid levels
ALEXANDER KAGAN, YAACOV BAR-KHAYIM, ZEHAVA SCHAFER, and MENAHEM FAINARU
Lipid Research Laboratory, Department of Medicine IA', and Division of Nephrology, Kaplan Hospital, Rehovot, Israel
Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein
leakage and its impact on plasma lipid levels. We quantified the plasma
levels and peritoneal loss of lipids and lipoproteins, and studied the
composition of plasma and effluent lipoproteins in 16 patients on CAPD
(5 females and 11 males, 18 to 76 years old). Five patients were studied
prospectively (at 0, 1, 3 and 6 months) and 11 patients at 6 to 58 months
on CAPD (N = 30). Elevated levels of plasma VLDL and reduced
levels of plasma HDL were maintained in these patients throughout 58
months of CAPD, whereas the initially increased LDL levels showed a
tendency towards normalization. All plasma lipoproteins (VLDL, IDL,
LDL and HDL) were present in the peritoneat effluent. The lipoproteins
isolated from plasma and peritoneal fluid shared a similar lipid and
apolipoprotein composition. The peritoneal transport characteristics of
plasma lipoproteins were similar to other plasma macromolecules.
Their clearance correlated with their molecular mass, plasma concen-
tration and dwell time, but was not affected by duration of CAPD
treatment. The plasma lipid and lipoprotein levels were unaffected by
the rate of glucose absorption. The peritoneal protein clearance corre-
lated positively with plasma levels of triglyceride and LDL, and
negatively with plasma HDL. An inverse correlation was observed also
between plasma levels of HDL and its peritoneal clearance (r =
—0.393,
P < 0.025, N = 30). The continuous peritoneal loss of HDL and the
hypertriglycendemia were found to contribute most to the persistent
low plasma levels of HDL in CAPD patients, and thus may lead to the
accelerated atherosclerosis observed in these patients.
Cerebrovascular and cardiovascular diseases are important
predictors for survival in patients undergoing continuous am-
bulatory peritoneal dialysis (CAPD), and account for about half
the deaths in these patients [1]. Abnormal plasma levels of
lipids and lipoproteins, such as increased cholesterol [2, 31,
LDL-cholesterol [41 or decreased HDL-cholesterol [5], are
associated with increased cardiovascular morbidity and mortal-
ity. The plasma lipid profile of patients on CAPD is abnormal
[6—81. Hypertriglyceridemia develops in almost half of the
patients on CAPD [9] and 29% of the patients acquire hyper-
cholesterolemia [10]. These changes result from increased
concentrations of these lipids in both VLDL and LDL fractions
[11]. On the other hand, the reduced plasma HDL-cholesterol
levels observed in patients with end-stage renal disease [12—14]
remain low during long-term CAPD treatment [10, 15—21].
Although CAPD is sixfold more efficient in the clearance of
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uremic toxins when compared to hemodialysis [22, 23], second-
ary hyperlipoproteinemia [24—26], predominantly type IV and
JIB according to Frederickson's classification [27], is more
prominent in CAPD patients [15, 28—31]. The reasons for these
persistent abnormalities have not been completely elucidated.
Thus, we undertook to investigate the effect of some putative
factors, previously suggested by other groups, that may con-
tribute to these abnormalities, such as protein loss of 5 to 15
g/day [32], glucose absorption of 150 to 300 g/day [33], and
lipoprotein loss into peritoneal effluent [34—37]. We have pro-
spectively studied a group of five patients starting their CAPD
treatment, and followed them for six months. In addition, we
have examined eleven patients at six to fifty-eight months on
CAPD treatment.
Methods
Patients
Sixteen patients (5 females and 11 males, aged 18 to 76 years)
with end-stage kidney disease and undergoing continuous am-
bulatory peritoneal dialysis were studied. The etiology of their
kidney disease and other clinical characteristics are detailed in
an accompanying manuscript [38] and Table 1. None of the
patients were obese, none suffered from diabetes mellitus,
nephrotic syndrome, liver disease or overt hyperlipidemia.
None of the patients had been previously treated by hemodial-
ysis, had a kidney transplant or was maintained on medications
known to affect plasma lipids. Five patients were recruited
before the start of CAPD treatment, and studied prospectively
for six months. The remainder eleven patients were studied at 6
to 58 months on CAPD. None of the studies were conducted
within one month of a peritonitis episode. The study was
approved by the Human Studies Committee of the Hospital,
and an informed consent was obtained from each subject.
Dialysis procedure
All patients had a Tenckhoff peritoneal catheter and were on
CAPD treatment for one day to fifty-eight months. They were
dialysed continuously with three to four exchanges daily, using
2 liter plastic bags of Travenol® Dianeal, 1.5% dextrose (Trave-
nol Laboratories, Ashdod, Israel). Doses of 4.25% dextrose,
dehydrating solutions were used intermittently when indicated.
The daily energy intake was about 30 Kcallkg in addition to
calories derived from dextrose in the dialysis fluid. The mean
daily protein intake was 1.5 g/kg of body weight, and their diet
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Table 1. Clinical characteristics and initial° blood analyses in studied patients
No. Age Sex
Etiology of
kidney disease
.Duration
of CAPD
months
BMI
kg/rn2
Glucose Creatinine
Total
protein Albumin
giliter
TG Chol
mrnol/litermmol/liter
1 40 F UNK 0—6 22.07 4.94 0.70 73.0 44.0 2.48 5.56
2 58 F CGN 0—6 25.76 5.60 1.21 72.0 42.0 2.71 6.20
3 42 F UNK 0—6 16.73 4.77 0.57 63.0 38.0 2.36 6.20
4 18 M CGN 0—3 16.78 4.22 0.70 61.0 37.0 2.60 5.43
5 73 M HT 0—3 25.78 5.82 0.92 73.0 44.0 1.92 6.33
6 59 M HT 6 28.39 4.88 1.09 73.0 40.0 1.13 4.37
7 35 M CPN 14,32 22.40 5.27 1.13 68.0 41.0 2.23 4.65
8 56 M UNK 18 28.88 5.22 0.88 74.0 40.0 1.66 5.27
9 66 F UNK 9 21.40 6.05 0.74 68.0 39.0 2.37 6.15
10 50 M UNK 16 19.77 5.05 1.14 76.0 46.0 2.59 6.36
11 53 M UNK 58 21.45 4.94 1.32 72.0 43.0 2.10 5.43
12 38 F UNK 28 22.77 5.33 1.01 69.0 38.0 2.03 5.87
13 39 M CGN 32 22.02 4.77 1.16 71.0 42.0 2.71 5.51
14 66 M PKD 12 21.33 5.17 0.82 66.0 40.0 0.99 5.30
15 63 M CGN 6 22.27 5.16 0.73 73.0 38.0 1.76 6.08
16 76 M CPN 31 26.56 5.44 0.57 72.0 38.0 2.20 3.78
Abbreviations are: BMI, Body Mass Index: body weight (kg)/height2 (m2); UNK, unknown; CGN, chronic glomerulonephritis; HT,
hypertension, CPN, chronic pyelonephritis; PKD, polycystic kidneys; TG, triglycerides and Chol, cholesterol.a Before the start of CAPD treatment
was supplemented with vitamins, calcium and aluminium hy-
droxide.
Study protocol
This is detailed in an accompanying manuscript [38]. In brief,
two liter bags of Travenol® Dianeal 1.5% dextrose solutions
were used for the exchanges. The effluents were collected in
each study following sequential cycles of varying dwell time:
eight hours (usually from midnight to 8 a.m.), four hours and
one hour, without disruption of CAPD. The patients were
recumbent and fasting during collection of samples (—17 hours).
Sample collection and analysis
During each study a venous blood sample was obtained at 8
a.m., following 12 hours of fasting. The blood was collected into
chilled tubes containing disodium EDTA (0.0 1% wt/vol final
concentration, pH 8.2). The dialysate effluents were collected
into cooled bags on ice and processed at 4°C. Their volume was
determined and centrifuged at 2500 x g for 20 minutes. One to
two liter aliquots were concentrated to 10 to 30 ml (30- to
100-fold) by means of membrane ultrafiltration, using a YM-lO
membrane and a 300 ml cell (Amicon Corp., Danvers, Massa-
chusetts, USA), at 4°C using N2 at 4 kg/cm2. The concentrated
fluid was dialyzed against five changes of 100 volumes of 0.15 M
NaCl containing 0.01% disodium EDTA pH 8.2 at 4°C. No
lipids or lipoproteins could be detected in the ultrafiltrates and
they were discarded.
Isolation of plasma lipoproteins
Blood samples were immediately centrifuged at 2500 x g for
20 minutes at 4°C. All procedures involving lipoprotein isolation
and characterization from both plasma and concentrated pen-
toneal effluents were started immediately and carried out at 4°C.
Preparative sequential flotation 139] of both plasma and perito-
neal effluent lipoproteins was achieved by centrifugation using
different KBr density solutions containing 1 mivi EDTA pH 8.2
in a 50.3 Ti rotor in an L8-70 Beckman ultracentrifuge (Beck-
man Instruments, Mountain View, California, USA). The fol-
lowing densities were used for the individual lipoproteins: very
low density lipoproteins (VLDL) at plasma and dialyzed ef-
fluent densities (d < 1.006 g/mI); intermediate density lipopro-
teins (IDL) at d = 1.006 to 1.019 g/ml; low density lipoproteins
(LDL) at d = 1.019 — 1.05 g/ml; high density lipoproteins2
(HDL2)atd= 1.063 — l.125g/mlandHDL3atd= 1.125— 1.21
g/ml. The lipoproteins were recovered by using a tube slicer
(Beckman Instruments) and were further purified by recentni-
fuging at the respective limiting KBr density solutions. All
centrifugations were carried out at 4°C for 18 to 20 hours at
40,000 rpm (HDL fractions were isolated over 44 hours). The
lipoproteins were dialyzed in the dark for 24 hours against five
changes of 100 volumes of 0.15 M NaCI, 1 mM EDTA pH 8.2 at
4°C, and used for determining the lipid and apolipoprotein
composition within one week.
Analytical methods
The partition of cholesterol among plasma and effluent lipo-
proteins was determined using the protocol of the Lipid Re-
search Clinics Manual [40], with some modifications. In brief, 6
ml of plasma or concentrated effluent were centrifuged in a 50.3
Ti rotor at 40,000 rpm for 18 hours at 4°C. The top layer
(containing the plasma VLDL) was removed by tube slicing.
The infranatant was brought back to the original volume by
adding 0.15 M NaCI, 1 mr'.'i EDTA pH 7.4, and cholesterol was
determined (LDL + HDL). The LDL was then precipitated
using hepanin-MnCl2 solution and cholesterol was determined
on the supernatant (HDL) following treatment with NaHCO3
[41]. The VLDL and LDL cholesterol concentrations were
calculated as follows: VLDL cholesterol =plasma or effluent —
1.006 gIml infranatant; LDL cholesterol = 1.006 g/ml infrana-
tant — HDL cholesterol.
Cholesterol [42] and triglyceride [43] were determined on
plasma, concentrated effluent and lipoproteins using commer-
cially available enzymatic kits (Boehringer-Mannheim, FRG
and Biotrol, Paris, France, respectively). Phospholipid content
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Table 2. Effect of duration of CAPD treatment on plasma levels of lipids, lipoproteins and apolipoprotein B
Months on dialysis
0
(5)b
1
(5)
3
(5)
6
(5)
9—18
(5)
28—58
(5) FC
Triglyceride mmol/titer 2.93 0.36
(+98.5 273%)"
3.55 0.63 2.98 0.28 3.46 0.71 3.15 0.52 3.37 0.42 0.20
Cholesterol mmot/liter 6.27 0.29
(+24.3 7.7%)"
7.36 0.83 6.34 0.53 6.39 0.48 5.78 0.53 5.27 0.31e 1.39
VLDL1mmoI/liter 1.66 0.18
(+201.7 731%)d
2.24 0.57 1.74 0.27 1.88 0.32 1.39 0.25 2.03 0.14 0.68
LDLmmot/liter 3.60 0.40
(+ 18.3 78%)d
4.08 0.45 3.60 0.33 3.46 0.32 3.27 0.36 2.31 0.27e 2.12
HDIfmmol/liter 1.01 0.03
(—15.8 35%)d
1,03 0.09 0.99 0.06 1.06 0.05 1.12 0.14 0.90 0.08 0.57
Apolipoprotein B gluier 1.21 0.05(+30.3 85%)d
1.30 0.01 1.25 0.05 1.28 0.14 1.12 0.09e 0.67 0.09 3.17
a The results represent 30 studies on 16 patients 0—58 months on CAPD (Table 1), and are expressed as mean SEM. The first study (0) was
performed following the completion of the training period (1—2 weeks).
b Figures in parentheses represent the number of patients studied at each time period.
C Analysis of variance, P < 0.05 when the value for F is greater than 2.8
d The values represent percent differences (mean sEM) between individual values when compared to the normal values for the Israeli
population of similar age and sex (52,53]
P < 0.05 by unpaired i-test when compared to values at 0 time
The plasma levels of VLDL, LDL and HDL are expressed as cholesterol mass associated with each lipoprotein
of lipoproteins was determined by the method of Bartlett [44],
following lipid extraction in chloroform: methanol, 2:1, vol/vol
[45]. The contribution of free cholesterol and cholesteryl ester
to total cholesterol was determined by the procedure of Chia-
mon and Henry [46], after separation of the extracted lipids by
thin layer chromatography as described previously [47].
Protein concentration in effluent and lipoproteins were deter-
mined by the method of Lowry et al [48]. Apolipoprotein
characterization was carried out by electrophoresis in sodium
dodecylsulfate (0.1%) polyacrylamide gel (11%) according to
the procedure described previously [49].
Apolipoprotein B in plasma and effluent samples was deter-
mined using a radial immunodiffusion method detailed previ-
ously [50].
Calculations and data analysis
The peritoneal mass transfer (mass/hr) and clearance (mll
mm) of lipids and lipoproteins were calculated as follows:
Ve Ce/T and Ve Ce/t P respectively, where: Ve total
dialysate effluent volume (ml); Ce = dialysate concentration of
lipids; t and T = dwell time in minutes and hours, respectively,
and P = plasma concentration. These calculations were used
for estimation of both mass transfer and clearance during the
studied dwell time of one, four and eight hours. For 1 to 4 hour
and 4 to 8 hour periods of an eight hour cycle the mass transfer
and clearance of solutes were calculated using the following
formulas: (Ce2 Ve2 — Ce1 Ve,)/(T2 — T1) and (Ce2 Ve2 —
Ce1 Ve1)/(t2 — t1) P respectively, where the subscript 2
represents the longer cycle (4 and 8 hr) and the subscript 1
represents the shorter cycles (1 and 4 hr, respectively).
All data were normalized for a body surface area of 1.73 m2
and evaluated by Student's t-test, analysis of variance, linear
regression and multiple linear regression [51] using a statpak
program (Northwest Analytical Inc., Portland, Oregon, USA).
Results
Plasma levels of lipids and lipoproteins during CAPD
Most studied patients had fasting plasma triglycerides and
cholesterol levels before the start of CAPD treatment exceeding
by about 50% and 12%, respectively, that of the mean normal
values of plasma lipid levels observed in the Israeli population
of similar age and sex [52] (Table 1). The effect of CAPD
treatment, up to 58 months, on the plasma levels of lipids,
lipoproteins and apolipoprotein B is detailed in Table 2. The
initial plasma levels of triglycerides and VLDL cholesterol in
the five patients studied prospectively exceeded by 98.5 and
201.7%, respectively, the normal limit of the Israeli population
of similar age and sex [52, 53]. These elevated plasma levels did
not change significantly during 58 months of dialysis (Table 2).
In contrast, the moderately increased plasma levels of total
cholesterol, LDL cholesterol and apolipoprotein B, which
exceeded by 24.3, 18.3 and 30.3%, respectively, the normal
limits for the Israeli population of similar age and sex [52, 53],
showed a tendency to decrease during long term CAPD (Table
2). Plasma HDL-cholesterol levels did not change during CAPD
and remained lower than the mean normal values for the Israeli
population of the same age and sex [52] (Table 2).
Lipoprotein loss into peritoneal fluid
Lipids and lipoproteins were detected in the peritoneal ef-
fluent of CAPD patients (Table 3). The peritoneal loss of
lipoprotein cholesterol mass was highest for LDL, lowest for
VLDL and intermediate for HDL. When this loss was ex-
pressed as peritoneal clearance of lipoprotein cholesterol, it
was highest for HDL and lowest for VLDL (Table 3). In view of
the known strong inverse correlation between peritoneal clear-
ance and the molecular mass of various proteins [38], we have
added the lipoprotein cholesterol clearance values to such a
plot. As observed in Figure 1, the lipoprotein clearance values
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Table 3. Peritoneal to
dun
ss of lipids, lipoproteins and apolipoprotein B
ng an 8 hour cycle of CAPD
Mass transfer Clearance
mg/hr/l.73 m2 ml/min/1.73 m2
Triglyceride 4.18 0.74 0.023 0.003
Cholesterol 6.69 0.72 0.046 0.005
VLDL 0.99 0.14 0.025 0.003
LDL 3.35 0.41 0.040 0.004
HDL 2.36 0.27 0.106 0.016
Apolipoprotein B 4.08 0.60 0.056 0.008
fitted the regression line of other plasma macromolecules, r =
—0.910, P < 0.0005. These results indicate to the presence of a
molecular sieving for lipoproteins in the peritoneal membrane
resulting in a selective loss of HDL, the lipoprotein with the
smallest diameter [541.
Composition of lipoproteins in plasma and the peritoneal
fluid
Chemical composition. Lipoproteins isolated from the pen-
toneal effluent have a similar chemical composition to the
respective plasma lipoproteins of the same patients (Table 4).
The composition of VLDL, IDL and LDL were almost identi-
cal. In contrast, the chemical composition of both HDL sub-
classes (HDL2 and HDL3) in the effluent showed a slight excess
of protein, phospholipid and free cholesterol (lipoprotein sur-
face constituents) and a slight decrease in triglyceride and
estenified cholesterol (lipoprotein core constituents), when
compared to plasma lipoproteins. These changes indicate
towards a preferable loss of smaller HDL particles in the
peritoneal fluid when compared to plasma lipoproteins [541 in
accordance with the characteristics of the peritoneal mem-
brane.
Apolipoprotein composition. All apolipoproteins known to be
associated with plasma lipoproteins were present in the perito-
neal lipoproteins. Furthermore, the profile of the apolipopro-
teins in the lipoproteins isolated from the peritoneal effluent
were indistinguishable from the respective lipoproteins isolated
from the plasma of the same patients (Fig. 2). This adds to the
accumulating evidence as to the plasma origin of the effluent
lipoproteins, filtered through the peritoneal membrane.
Kinetics of peritoneal loss of lipoproteins
The rate of lipoprotein loss into peritoneal fluid was related to
their respective molecular mass (Fig. 1). No statistically signif-
icant changes were observed in both the peritoneal mass
transfer and clearance of lipids, lipoproteins and apolipoprotein
B during 58 months of CAPD (Table 5). We examined next the
effect of cycle duration on the kinetics of lipoprotein loss. Both
the peritoneal mass transfer and clearance of LDL and HDL
showed a biphasic pattern during the eight hour dwell, in
accordance with our observations with other high molecular
weight proteins [38] (Fig. 3, Table 6). These values were lower
during the 1 to 4 hour when compared to 0 to I and 4 to 8 hour
periods of an eight hour cycle. VLDL did not show such a
biphasic pattern. In agreement with our observation with most
0 0.05 0.10
other macromolecules [381, the peritoneal mass transfer of
lipids, most lipoproteins and apolipoprotein B showed a posi-
tive linear correlation to their respective plasma levels (Fig. 4).
In contrast, the peritoneal mass transfer of HDL correlated
negatively with its plasma levels similarly to plasma albumin
[38] (Fig. 4).
Determinants of plasma lipids and lipoproteins level during
CAPD
The putative effect of some of the biochemical factors asso-
ciated with CAPD treatment on plasma lipids and lipoproteins
levels during CAPD treatment was tested by both univariate
and multivariate analyses. As expected from the lipoprotein
composition and the distribution of lipids among plasma lipo-
proteins [39], the strongest correlation was observed between
plasma VLDL cholesterol and triglycerides (r = 0.684, P <
0.0005), and plasma LDL cholesterol to total plasma cholesterol
(r = 0.858, P < 0.0005). Plasma HDL correlated negatively with
plasma triglyceride and VLDL (r = —0.588, P < 0.0005, and
—0.358, P < 0.05, respectively). The peritoneal loss of plasma
proteins, expressed as peritoneal clearance, correlated posi-
tively with both plasma triglycerides and LDL, and negatively
with plasma HDL levels (Table 7). Glucose absorption rate was
not correlated to plasma lipids or lipoprotein levels. The peri-
toneal clearance of LDL correlated positively, whereas the
peritoneal clearance of HDL correlated negatively with their
respective plasma levels (Table 7).
VLDL
The results represent 30 studies performed in 16 patients and are
expressed as mean SEM. All patients were recumbent and fasting.
Two liters of Dianeal 1.5% were used for exchanges (dwell time = 8
hours).
LDL
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Fig. 1. Effect of the molecular mass on the peritoneal clearance of
solutes calculated from 8 hour dwell time (patients 1-13, Table 1, N =
27). The regression equation obtained was: log Y = 7.27 — 21.86x; data
r 0.910; P < 0.0005. The data for the pentoneal clearance of plasma
proteins are taken from the accompanying manuscript [38].
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Table 4. Chemical composition of lipoproteins isolated from plasma and peritoneal effluent in patients undergoing CAPD
Lipoprotein
.
Density
g/ml Source
TGb FCb ECb PL1' Protein
wt/wt%
VLDL <1.006 Plasma
Effluent
()C
51.0 5.9
47.9 9.8
(NS)
6.8 1.5
7.6 1.9
(NS)
14.2 3.0
16.3 4.1
(NS)
15.4 3.5
16.5 3.2
(NS)
11.7 1.6
11.7 3.0
(NS)
IDL 1.006—1.019 Plasma
Effluent
(P)
33.2 6.7
32.5 7.2
(NS)
7.9 2.0
8.9 2.1
(NS)
23.9 5.7
24.2 3.7
(NS)
18.7 1.8
18.2 4.3
(NS)
16.2 1.7
16.3 1.9
(NS)
LDL 1.019—1.063 Plasma
Effluent
(P)
17.2 3.1
15.2 5.5
(NS)
9.5 2.0
12.0 2.7
(0.012)
31.2 3.5
30.0 4.4
(NS)
21.0 1.1
20.2 2.7
(NS)
21.2 4.0
22.6 2.4
(NS)
HDL2 1.063—1.l25 Plasma
Effluent
(P)
11.6 2.4
9.2 2.3
(0.015)
7.5 2.6
7.7 2.1
(NS)
24.1 4.3
21.7 3.6
(NS)
21.5 3.6
23.8 2.2
(0.033)
35.4 4.7
37.5 4.3
(NS)
HDL3 1.125—1.210 Plasma
Effluent
(P)
7,6 1.1
6.2 1.4
(0.0007)
3.3 1.4
4.8 2.3
(0.013)
14.6 2.2
14.3 3.3
(NS)
21.9 2.9
19.7 2.5
(0.028)
52.7 2.9
55.0 3.1
(0.045)
a The lipoproteins were isolated from the plasma and concentrated effluent (8 hr dwell) at the indicated density ranges, recentrifuged at the
respective density limits, dialysed and assayed. The results represent 22 paired studies performed in 13 patients and are expressed as % mass,
mean SD.
b TG, triglyceride; FC, unesterified cholesterol; EC, cholesteryl ester and PL, phospholipid
C TheP value was calculated from the two-tailed paired 1-test performed on results obtained from the respective effluent and plasma lipoproteins.
NS = P > 0.05
VLDL IDL LDL HDL2 HDL3
Fig. 2. Sodium dodecylsulfate (0.1%) polyacrylamide gel (11%) electrophoresis of lipoproteins isolated from plasma (P) and 8 hour effluents (E)
of CAPD patients. Lipoproteins were purified by sequential ultracentrifugation and dialyzed as detailed in Table 4. The lipoproteins were
delipidated in chloroform: methanol (3:1) and 75 g protein was applied to each gel. The gels were stained with coumassie brilliant blue [49]. For
identification of the stained proteins, purified apolipoproteins and albumin markers were run in parallel gels (not shown). Abbreviations: B -
apolipoprotein B; E - apolipoprotein E; A-I - apolipoprotein A-I; A-LI + C - apolipoproteins A-IL and C which comigrate in this gel system.
Discussion
The present results corroborate previous studies which dem-
onstrated that most abnormalities in plasma lipids and lipopro-
teins associated with end-stage kidney disease do not normalize
during CAPD treatment [6—8]. The elevated plasma levels of
cholesterol, LDL and apolipoprotein B showed only a slight
tendency to decrease. On the other hand, the elevated plasma
levels of triglyceride and VLDL, and the reduced plasma HDL
did not change significantly during 58 months of treatment.
Lipoprotein loss into peritoneal fluid
All plasma lipoproteins are present in the peritoneal fluid of
studied patients. They share a similar lipid and apolipoprotein
composition with their respective plasma lipoproteins indicat-
ing to their plasma origin. These results are consistent with the
observations made by Courtice and Roberts in the peritoneal
fluid of rabbits [55]. The similarity in the kinetic characteristics
of the peritoneal clearance of lipoproteins with that reported by
us for other macromolecules [38, 56] further support the sug-
gestion of the passive leakage from plasma. The peritoneal
permeability for lipoproteins increased with the decrease in
their molecular mass, resulting in a preferential loss of HDL,
the smallest of the lipoprotein particles. Moreover, this sieving
effect is also inferred from compositional analysis of HDL
subclasses. We observed a tendency to lose smaller particles in
both HDL2 and HDL3 fractions. In accordance with our obser-
vations with other high molecular weight proteins [38] the
peritoneal mass transfer and clearance of both LDL and HDL
B
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Table 5. Effect of duration of CAPD treatment on peritoneal clearance of lipids, lipoproteins and apolipoprotein B during an 8 hour cyclea
(Months on
dialysis)
0
(5)b
1
(5)
3 6
(5) (5)
9—18
(5)
28—58
(5)
ml/min/1.73 m2
Triglyceride 0.014 0.001 0.021 0.001 0.029 0.006 0.024 0.005 0.034 0.013 0.014 0.002
Cholesterol 0.037 0.008 0.043 0.010 0.047 0.008 0.045 0.009 0.069 0.022 0.036 0.005
VLDLC 0.018 0.006 0.023 0.009 0.027 0.006 0.026 0.007 0.040 0.013 0.015 0.003
LDLC 0.036 0.007 0.041 0.008 0.045 0.006 0.042 0.009 0.043 0.013 0.032 0.007
HDLC 0.075 0.018 0.105 0.032 0.092 0.022 0.093 0.020 0.181 0.073 0.089 0.005
Apolipoprotein B 0.039 0.009 0.051 0.011 0.061 0.015 0.080 0.025 0.049 0.015 0.048 0.010
a The results represent 30 clearance studies performed in 16 patients, 0-58 months on CAPD, and are expressed as mean SEM. 0,1 and 3 months
represent repeated studies in the prospective group (patients 1-5, Table 1) and the 6 months determination are studies performed in patients 1-3,6
and 15. The remainder were studied once at the time stated in Table I, in addition to patient 7 who was restudied at 32 months. All clearance values
were adjusted to 1.73 m2 body surface area. None of the differences were statistically significant by analysis of variance (F < 1.2).b Figures in parentheses represent the number of patients studied at each time period.
C The clearance of these lipoproteins is expressed as lipoprotein associated cholesterol.
E
C,,N
C
E
E
Fig. 3. Effect of dwell time on the 8-hour
peritoneal clearance of large molecular
weight solutes, (A) albumin (n), HDL (0),
IgG (U) and small solutes, (B) urea (0),
creatinine (n), glucose (U) (absorbed) in 13
patients on CAPD. The bars represent mean
SEM of 27 studies. The individual data were
calculated for the various dwell time intervals
as detailed in the Methods. (*) - represents
statistical significance (P < 0.05) by paired
Student's t-test compared with both 0—1 hr
Dwell time, hour and 4—8 hr intervals.
Table 6. Effect of dwell time on peritoneal loss of lipids and lipoproteinsa
Dwell time
Mass transfer
mg/h/I .73 m2
Clearance
mI/mm/I .73 m2
hours 0—1 1—4 4—8 0—1 1—4 4—8
Triglyceride
Cholesterol
VLDL
LDL
HDL
4.13 0.67
7.42 0.95
0.65 0.17
3.35 0.61
3.68 0.41
3.25 0.66"
5.30 0.62"
1.05 0.26
2.34 0.30
1.163 0.24"
5.35 1.38
7.94 1.17
1.19 0.24
3.89 0.68
2.76 0.51
0.023 0.003
0.048 0.005
0.018 0.005
0.050 0.007
0.161 0.019
0.018 0.004
0.037 0.006
0.033 0.011
0.030 0.004"
0.073 0012b
0.028 0.005
0.056 0.009
0.022 0.006
0.044 0.006
0.127 0.030
a The results represent 26 studies performed in 13 patients (1-13, Table 1) and are expressed as mean SEM. Two liters of Dianeala 1.5% were
used for three consecutive exchanges of 8, 4 and 1 hours. The lipid and lipoprotein cholesterol loss during the dwell times of 1—4 and 4—8 hours
were calculated from the 0—1, 0—4 and 0—8 hour losses.b p < 0.05 when compared to values obtained at 0—1 and 4—8 hour intervals, respectively
showed a biphasic pattern during an eight hour exchange. A tonic dialysate solution [57, 58], and a subsequent brief perito-
small but significant temporary decrease in both parameters neal interstitial dehydration [59], resulting in a transient delay in
was observed after the first hour of dialysis (ito 4 hr) with a the filtration of large molecules into the peritoneal fluid [60, 61].
subsequent increase to the initial rates (4 to 8 hr). This phenom- The peritoneal clearance of all lipoproteins was not affected
enon may be attributed to an early irritant effect of the hyper- by the duration of dialysis (up to 58 months), suggesting that the
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Table 7. Pearson's correlation coefficients between peritoneaI clearance of proteins, glucose and lipoproteins and plasma levels of lipids and
lipoproteinsa
.Plasma lipids Peritoneal clearance
and Total
lipoproteins protein Albumin Glucos&' Triglycerides Cholesterol VLDL LDL HDL
Triglycerides 0.314c 0.136 —0.023 0.197
Cholesterol 0.130 0.224 0.025 —0.079
VLDL 0.093 0.013 —0.039 —0.246
LDL 0.174 0.332e 0.081 0.318c
HDL 0.3l5c —0.144 —0.072
a Pearson's correlation coefficients (r values) were calculated from paired data obtained from 30 studies performed on 16 patients during 58
months of CAPD treatment. The peritoneal loss is expressed as clearance and calculated from a dwell of 8 hours
b The clearance of glucose expresses the absorption of glucose from peritoneum
P < 0.05
reduction observed in plasma LDL and apolipoprotein B during influence lipoprotein loss in CAPD patients; however, these
long-term CAPD treatment cannot be explained by changes in
the peritoneal permeability for LDL. Unlike the peritoneal
mass transfer of LDL and most other macromolecules [38]
which positively correlated with their respective plasma levels,
the peritoneal mass transfer and clearance of HDL disclosed an
inverse correlation with plasma HDL levels. This characteristic
of HDL is similar to that observed with serum albumin [38] and
highlights the importance of HDL loss during peritoneal dialysis
as a direct cause for lowering its plasma levels. Additional
changes in the peritoneal membrane permeability and the
lymphatic absorption from the peritoneal cavity [62] caused by
peritonitis, hypertonic solutes or vasoactive drugs may also
issues were not addressed in the present study.
Our previous observations indicate that the daily peritoneal
loss of low molecular weight proteins (<15000) and small
molecular weight solutes (<200) occurred mainly during the
first hour of three eight-hour cycles (>50% of the daily loss),
whereas only less than 17% of the daily loss occurred during the
4 to 8 hour intervals of an eight hour cycle [38]. On the other
hand, the daily peritoneal loss of high molecular weight proteins
(>68,000) including lipoproteins occurred mainly during the last
four hours of dwell (more than 50% of daily loss during the 4 to
8 hour intervals). Therefore, prolonged dialysis cycles are
wasteful (especially after four hours of dwell) when increased
A
Triglycerides
..........
B
VLDL
.
160804.'
E
- 400
>
200
2 4 6 8 10 0
Cholesterol
1 2 3 4
LDL
3 6 9 12 15 18
Apo B
160
80
50
30
10
) 2 4 6 8 10 Fig. 4. Correlation between plasma levels
HOL and 8 hour peritoneal mass transfer of lipids,
lipoproteins and apolipoprotein B in five
• CAPD patients studied prospectively for 6
months (N = 19, Table 1). The regression
equations obtained were: triglycerides: y =
192.7 + 23.7x; r = 0.579; P < 0.005;
cholesterol: y = 207.6 + 6.8x; r = 0.491, P <
0.025; apolipoprotein B: y = 104.3 + 4.3x; r
= 0.537, P < 0.01; VLDL: y = 57.4 + l5.3x;
I I
2 4 6 8 r = 0.375, P <0.05; LDL: y = 99.4 + ll.lx;
r = 0.699, P < 0.005; HDL: y = 44.2 — 2.lx;
mg/hr/!.73m2 r = — 0.502, P < 0.025.
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peritoneal loss of high molecular weight proteins (such as,
albumin, IgG and HDL) is not accompanied by significant
dialysance of small and "middle" molecules.
The presence of lipoproteins (3-lipoproteins) in the peritoneal
fluid of patients undergoing peritoneal dialysis was first re-
ported in 1964 by Berlyne et al [34]. In 1982 Breckenridge et al
demonstrated that the dialysis fluid of four CAPD patients
contained small amounts of HDL and LDL as well as insignif-
icant amounts of triglycerides and pre-f3-VLDL [35]. These
authors concluded that there is only little indication that the loss
of lipoproteins could account for changes in plasma lipoproteins
[35]. No significant transport of fat into the blood stream from
the peritoneal cavity in two patients on CAPD was also re-
ported [631. However, Mitwalli et al showed in rabbits that fat
emulsion is slowly absorbed through the peritoneal membrane
[64]. Saku et al [36] and Querfeld et al [37] reported the
peritoneal loss of apolipoproteins A-I, A-Il and B (major
apolipoproteins of HDL and LDL, respectively) during CAPD.
The former authors [36] suggested that continuous and selective
loss of HDL may lead to an increased predisposition of athero-
sclerosis in CAPD patients, while the latter authors [37] con-
cluded that the considerable loss of apolipoprotein A-I does not
affect the plasma levels of apolipoprotein A-I and HDL. Our
preliminary studies [65, 66] and the results of the present study
which demonstrate a strong inverse relationship between
plasma levels and peritoneal clearance of HDL, the magnitude
of this loss reaching about one-third of the daily synthetic rate
for HDL, and the results of regression analyses, support our
conclusions that HDL peritoneal loss contributes to its low
plasma level during CAPD.
Plasma triglycerides and VLDL levels
The plasma triglycerides and VLDL levels were increased in
our patients with end-stage kidney disease prior to CAPD
treatment, as reported by most investigators [6, 7, 10, 11, 24—26,
67, 68]. These elevated levels did not change significantly
during 58 months of CAPD treatment. Although the pathophys-
iology of the derranged lipid metabolism in uremic patients is
still unclear, evidence has been provided for both an increased
hepatic production and an impaired catabolism of circulating
triglyceride-rich particles [11, 15]. Lipoprotein lipase (LPL),
the main enzyme involved in VLDL catabolism is reduced in
patients with end-stage renal disease [69, 70]. It is known that
some middle molecular weight molecules from uremic serum
[71] and some peptide fractions found in the peritoneal dialysate
[72] are able to inhibit LPL activity. However, despite the
sixfold increase in the clearance of middle molecules in CAPD
patients when compared with hemodialysis [22, 23], LPL activ-
ity was shown to increase only slightly during 25 months of
CAPD [731, and its catabolic capacity for triglycerides did not
improve during peritoneal dialysis [21, 74]. On the other hand,
it has been suggested that the carbohydrate load [33] and the
protein waste [32] associated with CAPD may promote an
increased synthesis of VLDL in the liver. We observed no
correlation between the rate of peritoneal glucose absorption to
plasma triglycerides or VLDL levels. Similarly, no effect of
glucose absorption on hypertriglyceridemia has been noted in
several other studies [7, 10, 21, 75, 761. In contrast, Lindholm et
al reported a positive correlation between serum triglycerides
and the amount of dialysate glucose daily load [74]. This
discrepancy may be explained by a free use of hypertonic
dialysate and an unrestricted diet in the latter study [74], in
contrast to our patients and that of the former series [11].
Recently it was found that despite the enhanced hepatic syn-
thesis of lipoprotein lipids which may be stimulated by a
decreased plasma albumin concentration or oncotic pressure
[77], the hypertriglyceridemia associated with the nephrotic
syndrome is not caused primarily by overproduction of VLDL,
but is a result of delayed lipolysis of VLDL triglycerides, even
when the renal function is preserved [78]. In CAPD patients,
the daily peritoneal loss of proteins is in the nephrotic range (5
to 15 g/day) [32, 38] and is associated with a decrease of serum
albumin level [79]. The serum levels of albumin and other
plasma proteins in our patients were maintained at the lower
normal limits [38], but did not correlate with plasma triglyceride
or VLDL levels. On the other hand, only a weak positive
correlation was observed between peritoneal protein loss and
plasma triglycerides but not VLDL. Therefore, we agree with
the findings of Rubin, Walsh and Bower who concluded that
CAPD can not be considered a model for the nephrotic syn-
drome [20].
Plasma cholesterol, LDL and apolipoprotein B levels
The elevated plasma levels of cholesterol, LDL and apolipo-
protein B observed prior to initiation CAPD treatment in our
patients fell slowly during long term CAPD. These findings are
consistent with most previous reports [7, 10, 11, 79—81]. We
found no correlation between the peritoneal loss absorption of
glucose and changes in plasma cholesterol or LDL levels,
which is similar to previous reports [20, 21]. On the other hand,
plasma LDL levels in our patients correlated positively with the
peritoneal clearance of both albumin and LDL. Our results are
compatible with the proposed mechanism for elevated LDL in
nephrotic patients, namely increased hepatic synthesis [77, 78],
particularly in conditions associated with an increased perito-
neal permeability caused by peritonitis, the use of hypertonic
dialysate, vasodilators and very long or very short dwell time
cycles. The observed tendency for normalization of plasma
levels of both LDL and its associated apolipoprotein B indi-
cates an improvement of cholesterol metabolism during CAPD
treatment. This suggestion is supported by the findings of
Dieplinger, Schoenfeld and Fielding, who demonstrated choles-
terol metabolic rates within the normal range in patients treated
by CAPD [82].
Plasma HDL level
The plasma HDL level in our patients was reduced prior to
CAPD treatment and did not change during long term of CAPD
(up to 58 months), confirming most previous reports [7, 10,
15—21]. In some of the earlier studies, however, a slight increase
of plasma HDL cholesterol level has been observed during a
three to six month period on CAPD [18, 35, 83]. Khanna et al
reported an increase in HDL cholesterol after three to six
months of CAPD only in individuals with normal initial plasma
triglycerides, in contrast to reduced HDL level in hyperlipid-
emic and diabetic subjects [7]. Some investigators reported
higher levels of HDL during CAPD, when compared to hemo-
dialysis patients [15], while others demonstrated inverse results
[84].
HDL is synthesized and secreted by the liver [85] and gut [86]
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independently of triglyceride-rich lipoproteins [871. Some lipid
and protein constituents which are released during the metab-
olism of triglyceride-rich lipoproteins (VLDL and chlomicrons)
and tissue derived cholesterol may also contribute to plasma
HDL [85]. Two enzymes appear to be important for the
production and maintaining of plasma HDL levels: lecithin
cholesterol acyl tranasferase (LCAT), responsible for the ester-
ification of cholesterol in plasma, and LPL, which releases
surface components from triglyceride-rich lipoproteins [85].
Both enzymes have been reported to be reduced in CAPD
patients [73]. The negative effect of hypertriglyceridemia and
increased VLDL level on plasma HDL observed in our patients
support this view. Recently a significant inverse correlation has
been reported between serum creatinine and HDL level in
nondialyzed patients with chronic renal failure [12, 13, 68]. Our
results showed no such correlation during CAPD treatment;
however, both serum concentration and peritoneal clearance of
urea influenced plasma HDL when analyzed by linear but not
by multiple regression, indicating probably to the role of protein
intake and degradation or dialysis efficiency in regulating
plasma HDL level. The effect of urea as "uremic toxins" [88]
has not been excluded.
Plasma HDL level was inversely correlated with its perito-
neal clearance suggesting an effect of this loss on plasma levels.
This observation disagrees with the conclusion reached by
Breckenridge et al [35] who excluded a potential role for
lipoprotein losses. It has been reported that on a balanced
isocaloric diet, the mean daily synthetic rate for HDL protein is
8.51 mg/kg [80]. Taking into account the composition of HDL
(cholesterol to protein ratio of 0.34) [80], we may calculate the
synthetic rate for HDL cholesterol as 2.89 mg/kg per day. In our
patients the daily peritoneal loss of HDL cholesterol was 57
6 mg (mean SEM) or 0.97 mg/kg body weight, which reaches
33.6% of the daily synthetic rate for HDL cholesterol. Thus, we
feel that the effect of HDL peritoneal loss in maintaining low
plasma HDL levels was underestimated in the previous study
[35]. The strong inverse correlation between plasma levels and
peritoneal clearance of HDL observed in the present study
further supports our suggestion. Similarly, Saku et al have
demonstrated that the low plasma HDL levels in nephrotic
patients result, at least in part, from an accelerated catabolism
through urinary loss [89].
Conclusions
CAPD is associated with a loss of all plasma lipoproteins into
the dialysate through a molecular sieving effect of the peritoneal
membrane. The elevated plasma cholesterol, LDL and apo B
levels observed in end-stage kidney disease tend to normalize
during such a treatment. On the other hand, the increased
triglyceride and VLDL levels, and the reduced HDL level
observed in chronic renal failure do not change significantly
during this supportive treatment.
Both the hypertriglyceridemia and the continuous peritoneal
loss of HDL contribute to the persistent low levels of plasma
HDL in CAPD patients, suggesting both an increased catabo-
lism and defective metabolism of plasma HDL. A better under-
standing of the causes of hypertriglyceridemia observed in
these patients leading to effective treatment and lowering of
plasma triglycerides on one hand, and the development of more
effective methods for dialysis that will minimize HDL loss into
the peritoneal fluid may result in elevation of plasma HDL.
Consequently, a reduction in the rate of accelerated atheroscle-
rosis in these patients may be expected.
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